• GenScript Biotech’s Legend Biotech unit flagged updated long-term data for CARVYKTI from the CARTITUDE-2 program at IMS 2026.
• Results will be presented September 23-26, 2026, with a focus on earlier-line, lenalidomide-refractory multiple myeloma.
• The update highlights durable remission and survival signals in CARTITUDE-2 Cohort A, supporting CARVYKTI’s positioning beyond late-line use.
• Additional posters will cover real-world outcomes and an early readout from a post-authorization safety study, aimed at validating performance in routine care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100800PRIMZONEFULLFEED9824373) on September 10, 2026, and is solely responsible for the information contained therein.